Researchers Identify Protein Target to Undermine Glioblastoma Resistance

Researchers at The Ohio State University Comprehensive Cancer Center identified the protein SET as a key blocker of the tumor-suppressing enzyme PP2A in glioblastoma cells. In preclinical experiments, eliminating SET stopped tumors from developing, and targeting associated proteins such as ANP32A and CIP2A heightened the cancer cells' vulnerability to radiation. By reactivating PP2A, the strategy could enhance the impact of existing chemotherapy and radiotherapy regimens.

The study also explored an FDA-approved antipsychotic that boosts PP2A activity, though it is not yet approved for cancer use. Findings were published in the May 2026 issue of Cancer Letters and funded by NIH, the National Cancer Institute, and the university’s cancer center. Further research will determine whether this method is safe and effective in patients.